Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), effectively neutralises both Alpha and Delta variants of coronavirus, revealed the studies recently conducted by the US’ National Institute of Health (NIH). Two studies were carried out wherein blood serum from people who had received Covaxin was collected and examined. The results suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively, said NIH, the top American health research institute, in its press release.